From paper to the cloud

The author also describes the benefits of a cloud platform in terms of collaboration among different research and development teams.
The development of an approved gene therapy is currently focused on adeno-associated virus (AAV)-based gene therapies for the treatment of patients affected by hemophilia, Huntington’s disease, and other severe genetic disorders. A modular, validated cloud platform is used for this purpose. However, before the switch to a cloud-based platform, paper-based workflows make it difficult to track test results and facilitate cross-team and cross-site collaboration. This is the case for many life sciences companies, as digitalization is not progressing very quickly, particularly in research and development (R&D) departments. Read here the article here.